Investor Presentaiton

For personal use only · Prostate cancer therapy assets overview Next-generation therapy to follow TLX591 Target: Prostate Specific Membrane Antigen (PSMA) • • Indication: Prostate cancer Target: PSMA TLX591 TLX592 Clinical status: . TLX591: ProstACT GLOBAL Phase III + ancillary studies recruiting TLX592: CUPID study enrolling patients for imaging initially – next-generation PSMA-directed alpha therapy Rationale: • Unmet need for treatment options for late-stage, metastatic patients specifically target both soft tissue and bony lesions Antibody-based PSMA treatment may deliver superior efficacy and side-effect profile compared to small molecule TLX592 a potential adjuvant for high-risk patients that may have early metastatic disease. May also have utility in patients progressing from conventional 177 Lu-PSMA Tx Targeting molecule Antibody Engineered Antibody Targeting agent DOTA- rosopatamab RADmAbⓇ Radionuclide 225AC 177Lu Telix Pharmaceuticals Limited (ASX: TLX) 28 TELIX PHARMACEUTICALS

View entire presentation